ATL-001 (Achilles Therapeutics)
- Generic Name
- ATL-001 (Achilles Therapeutics)
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC
Phase 1
Terminated
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Achilles Therapeutics UK Limited
- Target Recruit Count
- 27
- Registration Number
- NCT04032847
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
ATL001 in Patients With Metastatic or Recurrent Melanoma
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Achilles Therapeutics UK Limited
- Target Recruit Count
- 13
- Registration Number
- NCT03997474
- Locations
- 🇪🇸
Instituto de Investigación Sanitaria Fundación Jimenez DÃaz, Madrid, Spain
🇪🇸Centro Integral Oncologico Clara Campal (CIOCC) Hospital Universitario HM Sanchinarro, Madrid, Spain
🇬🇧Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath